Genomics and Efficacy of Post-prostatectomy Salvage Radiotherapy With 'Extreme' Hypofractionation

Launched by REGINA ELENA CANCER INSTITUTE · Mar 18, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new way to treat men who have had prostate surgery but are experiencing a rise in their prostate-specific antigen (PSA) levels, which indicates the return of cancer. The treatment being tested is called salvage radiotherapy, which is a type of radiation therapy given after surgery. In this trial, researchers will use a specific genomic test called Decipher® to help determine the best approach to treatment. This test looks at 22 genes in the patient's cancer to give more information about the disease and how it might respond to the radiation therapy.

To be eligible for the trial, participants need to be male and meet certain criteria set by the study protocol. They must also agree to take part in the study by signing a consent form. Participants can expect to receive targeted radiation therapy and will be monitored closely throughout the trial. This study is currently recruiting participants, and taking part could help improve treatment options for men in similar situations in the future.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • patients enrolled at IRE under the "esSBRT" protocol (meeting the criteria of the same);
• • patients who express written informed consent personally or through their legal representative/witness/curator/guardian/support administrator (participation in the ancillary study and data processing)
• Exclusion Criteria:
• • all exclusion criteria adopted for the "esSBRT" study.